


[0012] In another aspect, a compound is provided represented by:




wherein:


R^1, R^2, R^3, and R^4 are each independently selected from the group consisting of hydrogen; halogen, C_1-C_6alkyl, or –OH;

R^5 is ~~H or~~ -CH_2-phenyl (wherein the phenyl is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, C_{1-3}alkoxy, and C_{1-3}alkyl (optionally substituted by one, two or three halogens)), provided that R^5 is -CH_2-phenyl when R_1 and R_3 are –OH and R_2 and R_4 are methyl; and


X is selected from the group consisting of OR^x and NR^xR^x, wherein R^X is independently selected, for each occurrence, from the group consisting of hydrogen, and C_1-C_6alkyl; pharmaceutically acceptable salts, stereoisomers, and hydrates thereof.

[0013] For example, a contemplated compound may be represented by:





7. A compound represented by:



wherein


R^1, R^2, R^3, and R^4 are each independently selected from the group consisting of hydrogen; halogen, C_1-C_6alkyl, and -OH;

R^5 is ~~H or~~ $-CH_2$-phenyl (wherein the phenyl is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, C_{1-3}alkoxy, and C_{1-3}alkyl (optionally substituted by one, two or three halogens)), provided that R^5 is $-CH_2$-phenyl when R_1 and R_3 are -OH and R_2 and R_4 are methyl; and

X is selected from the group consisting of OR^x and NR^XR^X, wherein R^X is independently selected, for each occurrence, from the group consisting of hydrogen, and C_1-C_6alkyl;


pharmaceutically acceptable salts, stereoisomers, and hydrates thereof.

8. The compound of claim 7 represented by:




or


~~9. The compound of claim 7 represented by:~~




~~or~~







~~10. The compound of claim 7 represented by:~~



~~11~~9. The compound of claim 7 represented by:



, or .

~~12~~10. A pharmaceutical composition, comprising:

a therapeutically effective amount of a compound of any one of claims 1-~~11~~9 and a pharmaceutically acceptable carrier.

~~13~~11. The pharmaceutical composition of claim ~~11~~10, ~~suitable for injection~~wherein the pharmaceutical composition is an injectable composition.

~~14~~12. Use of a compound of any one of claims 1-~~12~~9 in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, ADHD, schizophrenia, or anxiety.

~~15~~13. Use of a compound of any one of claims 1-6 in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, ADHD, schizophrenia, or anxiety, wherein the medicament is to be administered orally.

~~16~~14. Use of a compound of any one of claims 8 or ~~11~~9 in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, ADHD, schizophrenia, or anxiety, wherein the medicament is to be administered subcutaneously or intravenously.